Limited antifungal diversity and availability are growing problems for the treatment of fungal infections in the face of increasing drug resistance. The echinocandins, one of the newest classes of antifungal drugs, inhibit production of a crucial cell wall component. However, these compounds do not effectively inhibit the growth of the opportunistic fungal pathogen , despite potent inhibition of the target enzyme Therefore, we performed a forward genetic screen to identify cellular processes that mediate the relative tolerance of this organism to the echinocandin drug caspofungin. Through these studies, we identified 14 genetic mutants that enhance caspofungin antifungal activity. Rather than directly affecting caspofungin antifungal activity, these mutations seem to prevent the activation of various stress-induced compensatory cellular processes. For example, the Δ mutant has defects in the palmitoylation and localization of many of its target proteins, including the Ras1 GTPase and the Chs3 chitin synthase, which are both required for caspofungin tolerance. Similarly, we have confirmed the link between caspofungin treatment and calcineurin signaling in this organism, but we suggest a deeper mechanism in which caspofungin tolerance is mediated by multiple pathways downstream of calcineurin function. In summary, we describe here several pathways in that contribute to the complex caspofungin tolerance phenotype in this organism.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727808 | PMC |
http://dx.doi.org/10.1534/genetics.119.302290 | DOI Listing |
Microbiol Spectr
December 2024
Laboratório de Bioquímica e Imunologia das Micoses, Departamento de Microbiologia e Parasitologia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.
Unlabelled: is an emerging fungal pathogen notable for its resistance to multiple antifungals and ability to survive in various environments. Understanding the interactions between and environmental protozoa, such as could provide insights into fungal adaptability and pathogenicity. Two isolates (MMC1 and MMC2) were co-cultured with to examine interaction dynamics, survival, stress responses, growth, virulence, biofilm formation, and antifungal susceptibility.
View Article and Find Full Text PDFJ Fungi (Basel)
October 2024
School of Pharmaceutical Sciences of Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto 14040-903, Brazil.
can cause invasive pulmonary aspergillosis (IPA). Fungicidal azoles and fungistatic caspofungin (CAS) are the first- and second-line therapies, respectively, used to treat IPA. Treatment of with CAS or micafungin induces the production of the oxylipin 5,8-diHODE by the fungal oxygenase PpoA.
View Article and Find Full Text PDFCrit Care
October 2024
Médecine Intensive Réanimation, Inserm U1285, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, CHU de Lille, Université de Lille, Lille, France.
Background: Rezafungin is an echinocandin approved in the US and EU to treat candidaemia and/or invasive candidiasis. This post-hoc, pooled analysis of the Phase 2 STRIVE and Phase 3 ReSTORE trials assessed rezafungin versus caspofungin in patients with candidaemia and/or invasive candidiasis (IC) in the intensive care unit (ICU) at randomisation.
Methods: STRIVE and ReSTORE were randomised double-blind trials in adults with systemic signs and mycological confirmation of candidaemia and/or IC in blood or a normally sterile site ≤ 96 h before randomisation.
Ann Pharm Fr
October 2024
Service pharmacie, groupement hospitalier Nord, hospices civils de Lyon, Lyon, France; ISPB, faculté de pharmacie de Lyon, université de Lyon, université de Lyon 1, Lyon, France; UMR CNRS 5558, laboratoire de biométrie et biologie évolutive, université de Lyon, université de Lyon 1, Villeurbanne, France.
Given its good tolerance and broad-spectrum, isavuconazole is increasingly used off-label as an empirical therapy of invasive fungal infections. We retrospectively reviewed isavuconazole empirical treatment during a 12-month period in four hospitals. During isavuconazole treatment (n=27), none of the patients had a mycological evidence for fungal infection, but 19% (5/27) developed liver test abnormalities without leading to isavuconazole discontinuation.
View Article and Find Full Text PDFPharm Dev Technol
November 2024
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, Granada, Spain.
Aim: Oral candidiasis is often challenging due to limited effectiveness of topical treatments. This study aimed to develop novel caspofungin formulations for administration onto the oral mucosa to enhance drug retention and efficacy.
Method: Five caspofungin (2%, w/v) formulations were developed to assess their permeability, retention and mucoadhesiveness.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!